YDES Stock Forecast: YD Bio Ltd. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$4.83
+5.92% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 3 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$342.1M
Ticker Nerd rank
3/ 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
−1.0%
1M
−17.3%
YTD
−60.4%
1Y
−42.2%
From 52W high
−68.7%
From 52W low
+154.2%
$2
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores YD Bio Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
3/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
69
Momentum
26
Revisions
20
Issuance
16
Growth
10
Accruals
5
Value
2
Quality
1

Volatility (69): The share price has been relatively steady.

Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

YDES stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on YDES, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26YDES

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

YDES appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

YDES vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, YD Bio Ltd. returned −42.2% against +6.9% for the S&P 500, dividends included.

YDES vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26YDESS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

YDES analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
276.1×

Cheaper than 2% of US stocks

Price / book
76.7×

Cheaper than 1% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
314.9%

Higher than 97% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
24.7%

Higher than 84% of US stocks

Returns & dividend
Return on equity
291.0%

Higher than 99% of US stocks

Return on assets
−60.3%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • YD Bio Ltd. has a market value of $342.1M and an enterprise value of $339.5M.

  • Shares outstanding: 70.8M.

  • YD Bio Ltd. employs 13 people.

market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

YDES and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
YDESYD Bio Ltd.$342.1M3
ALECAlector, Inc.$346.2M94
LYELLyell Immunopharma, Inc.$338.2M80
CTNMContineum Therapeutics, Inc.$336.4M32
LRMRLarimar Therapeutics, Inc.$331.6M29
MPLTMapLight Therapeutics, Inc.$330.1M16
INOInovio Pharmaceuticals, Inc.$329.7M49

Take a look at YDES’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own YD Bio Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about YDES

How does Ticker Nerd's model rank YDES?

As at 21 Nov 2026, YD Bio Ltd. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (69 of 100).

What is the YDES stock forecast for 2030?

No analyst covering YD Bio Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for YDES are extrapolating price history, which says nothing about the business.

How has YDES stock performed over the past year?

YD Bio Ltd. returned -42.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does YD Bio Ltd. do?

YD Bio Limited is a biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization. Its current portfolio includes DNA methylation-based cancer detection programs, ophthalmologic products, stem cell- and exosome-based therapeutics, and clinical trial drug supply services.

Company

About YD Bio Ltd.

YD Bio Limited is a biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization. Its current portfolio includes DNA methylation-based cancer detection programs, ophthalmologic products, stem cell- and exosome-based therapeutics, and clinical trial drug supply services. The company also works in blood-based oncology testing, early cancer detection, treatment monitoring, and recurrence tracking, while serving pharmaceutical and biotechnology partners with compliant distribution and clinical trial support. Based in Taipei, Taiwan, YD Bio Limited operates as an integrated healthcare platform spanning diagnostics, regenerative medicine, eye care, and related commercial healthcare markets.

CEO Dr. Ethan Shen Ph.D. · 13 employees · Taiwan · https://www.ydesgroup.com